The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients

European Journal of Clinical Pharmacology

Volumn 64, Issue 4, 2008, Pages 367-372

  Dragonas, Charalampos ^a   Wagner, Jan T ^a   Heppner, Hans J ^a   Bertsch, Thomas ^b   Muhlberg, Wolfgang ^a   Wicklein, Susanne ^a   Pahl, Andreas ^a   Diewald, Christine ^a   Bachmakov, Iouri ^a   Sieber, Cornel C ^a   Fromm, Martin F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

Author keywords

ABCB1; Digitoxin; Geriatric; P glycoprotein; Polymorphism

Indexed keywords

DIGITOXIN; MULTIDRUG RESISTANCE PROTEIN 1;

AGED; AMINO ACID ANALYSIS; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE REGIMEN; FEMALE; GENETIC ASSOCIATION; GENOTYPE; GERIATRIC HOSPITAL; GERIATRIC PATIENT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANALYSIS OF VARIANCE; CARDIOTONIC AGENTS; DIGITOXIN; FEMALE; GENOTYPE; HUMANS; MALE; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 40049108933     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0418-x     Document Type: Article

References (35)

1. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK (1993) Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. Radiance Study. N Engl J Med 329(1):1-7
2. Warren JL, McBean AM, Hass SL, Babish JD (1994) Hospitalizations with adverse events caused by digitalis therapy among elderly Medicare beneficiaries. Arch Intern Med 154(13):1482-1487
3. Aronow WS (1996) Prevalence of appropriate and inappropriate indications for use of digoxin in older patients at the time of admission to a nursing home. J Am Geriatr Soc 44(5):588-590
4. Passmore AP, Johnston GD (1991) Digoxin toxicity in the aged. Characterising and avoiding the problem. Drugs Aging 1(5):364-379
5. Mauskopf JA, Wenger TL (1991) Cost-effectiveness analysis of the use of digoxin immune Fab (ovine) for treatment of digoxin toxicity. Am J Cardiol 68(17):1709-1714
6. Kelly RA, Smith TW (1992) Recognition and management of digitalis toxicity. Am J Cardiol 69(18):108G-118G
7. Muhlberg W, Platt D (1999) Age-dependent changes of the kidneys: pharmacological implications. Gerontology 45(5):243-253
8. Roever C, Ferrante J, Gonzalez EC, Pal N, Roetzheim RG (2000) Comparing the toxicity of digoxin and digitoxin in a geriatric population: should an old drug be rediscovered? South Med J 93(2):199-202
9. Storstein O, Hansteen V, Hatle L, Hillestad L, Storstein L (1997) Studies on digitalis. XIII. A prospective study of 649 patients on maintenance treatment with digitoxin. Am Heart J 93(4):434-443
10. Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF (2003) P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 73(3):223-231
11. Pauli-Magnus C, Murdter T, Godel A, Mettang T, Eichelbaum M, Klotz U, Fromm MF (2001) P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol 363(3):337-343
12. de Lannoy IA, Silverman M (1992) The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 189(1):551-557
13. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P (1995) Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96(4):1698-1705
14. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM (1999) Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99(4):552-557
15. Ayrton A, Morgan P (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31(8-9):469-497
16. Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25(8):423-429
17. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104(2):147-153
18. Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75(1):13-33
19. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97(7):3473-3478
20. Kolenda KD, Jost S, Kokenge F (1981) Digoxin or digitoxin? Glycoside choice in old age and in kidney and liver diseases. Ther Ggw 120(1):21-39
21. Klauser-Reucker C, Ferrini B, Klauser H, Moccetti T (1975) Proceedings: clinical value of serum digoxin and digitoxin determination in renal insufficiency. Schweiz Med Wochenschr 105(51):1784-1786
22. Zolk O, Jacobi J, Pahl A, Fromm MF, Schmieder RE (2007) MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet Genomics 17(2):137-144
23. Belz GG, Breithaupt-Grogler K, Osowski U (2001) Treatment of congestive heart failure-current status of use of digitoxin. Eur J Clin Investig 2:10-17
24. Fulton MM, Allen ER (2005) Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 17(4):123-132
25. Bohmer T, Roseth A (1998) Prolonged digitoxin half-life in very elderly patients. Age Ageing 27(2):222-224
26. Sieber CC (2005) The concept of frailty-from phenomenology to therapeutic approaches. Z Gerontol Geriatr 38:11-13
27. Muhlberg W, Sieber C (2004) Sarcopenia and frailty in geriatric patients: implications for training and prevention. Z Gerontol Geriatr 37(1):2-8
28. Lukas DS (1971) Some aspects of the distribution and disposition of digitoxin. Ann N Y Acad Sci 179:338-361
29. Erdmann E (1991) Peculiarities of cardiac glycoside therapy in the aged. Internist 32(8):472-478
30. Fromm MF (2002) The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 54(10):1295-1310
31. Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ (2006) Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 79(6):540-548
32. Brenner SS, Klotz U (2004) P-glycoprotein function in the elderly. Eur J Clin Pharmacol 60(2):97-102
33. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146-156
34. Stewart RB, Caranasos GJ (1989) Medical compliance in the elderly. Med Clin North Am 73(6):1551-1563
35. Luke M, Dasgupta A (1997) Digitoxinlike and digoxinlike immunoreactivitis in sera of patients with uremia and liver disease as measured by fluorescence polarization immunoassays: poor correlation between digitoxinlike and digoxinlike immunoreactivities. Ther Drug Monit 19(2):230-235